Evidence map›Paper›PMID 40719810›Full record

ReviewAnnals of hematology2025

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges.

Yao Wang, Yaping Zhang, Jiaqi Liu, Yongning Jiang, Jianyong Li, Wenyu Shi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yao Wang *Department of Hematology, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, China.
Yaping Zhang *Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.
Jiaqi Liu *Nantong University, Nantong, China.
Yongning Jiang *Nantong University, Nantong, China.
Jianyong LiDepartment of Hematology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. lijianyonglm@126.com.
Wenyu ShiDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, China. shiwenyu@hotmail.com.

Funding

Jiangsu Province Capability Improvement Project through Science, Technology and Education ZDXK202234Jiangsu Provincial Research Hospital Project YJXYY202204-XKB17Postdoctoral Science Foundation of Guangxi Province of China No:2019M660127Postdoctoral Science Program Foundation of Jiangsu Province, China No:2019Z146Project of the 14th Five Year Plan for Strengthening Science, Education, and Health of Nantong City, Cancer Clinical Medical Center NTYXZX18the 2024 Provincial Basic Research Special Fund (Natural Science Foundation) General Project: The Role and Mechanism of Abnormal Arginine Metabolism in the Progression of Peripheral T-cell Lymphoma BK20241837the Science and Technology Project of Nantong City MS22022111
6 · The paper itself

Abstract

Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, is crucial for the development of B-cell malignancies. Covalent BTK inhibitors (cBTKis), such as ibrutinib, have demonstrated remarkable efficacy, but their curative potential is limited by acquired resistance. Next-generation BTK inhibitors, including non-covalent BTK inhibitors and BTK Proteolysis-targeting chimeras, offer new options for patients who have developed resistance to cBTKis. Some of these inhibitors have shown favorable efficacy and safety profiles, leading to Food and Drug Administration approval. This review summarizes the current landscape of BTK inhibitors, focusing on the evolution from cBTKis to next-generation inhibitors in terms of clinical efficacy and challenges, such as resistance mechanisms and off-target effects. We conclude with an outlook on future research and clinical applications.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsLeukemia, B-CellLymphoma, B-CellProtein Kinase InhibitorsAdenineDrug Resistance, NeoplasmHumansPiperidinesProteolysisTyrosine Kinase InhibitorsAdenineAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanibrutinibPiperidinesProtein Kinase InhibitorsTyrosine Kinase InhibitorsB-cell malignanciesBruton tyrosine kinaseBTK PROTACsEfficacyNon-covalent BTK inhibitorsSafety

Identifiers

PMID40719810
PMCPMC12432053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.